Kangrun Biological-B (06922.HK) announces its interim results, with a net loss attributable to the parent company's owners of 23.817 million yuan, a decrease of 54.35% year-on-year.

Zhtng Cijng APP newsletter, Kangfeng Biology-B (06922.HK) announced its mid-term performance for 2025, with a revenue of 51.106 million yuan, a year-on-year increase of about 1.62 times; gross profit of 34.312 million yuan, a year-on-year increase of about 1.25 times; the loss attributable to owners of the parent company was 23.817 million yuan, a year-on-year narrowing of 54.35%; and a loss per share of 0.1 yuan.